Overview
(March 2, 2021, New York) — Steptoe partner John Molenda has been named to The National Law Journal's 2021 list of Trailblazers in Healthcare and Life Sciences. The list is featured in a supplement in the March issue of the legal publication.
Molenda, co-chair of Steptoe's Healthcare & Life Sciences practice, has been at the forefront of litigation and thought leadership in the new wave of large-molecule therapeutics known as biologics. His practice focuses on high-stakes life sciences patent litigation before district courts, the Federal Circuit court of appeals, and the Patent Office.
In Hatch-Waxman litigation, Molenda has served as lead counsel for generic Apotex regarding blockbuster chemotherapies and blood clotting disorder products, while also serving as lead counsel for innovator Orexo regarding opioid formulations. As for biologics, Molenda led Steptoe's team successfully representing innovators Sanofi and Regeneron in Amgen v. Sanofi, a groundbreaking case involving antibody therapies used to treat high cholesterol, while also coordinating pre-litigation strategy for Apotex’s global biosimilars program.
Molenda's experience litigating both Hatch-Waxman and biologics cases earned him a 2019 Life Sciences MVP award by Law360, and in 2020, IAM Patent 1000 recognized him as an "extremely smart and meticulous" litigator who has created a "strong [brand] on both the small and large molecule sides."
About Steptoe
In more than 100 years of practice, Steptoe has earned an international reputation for vigorous representation of clients before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and other professional staff across offices in Beijing, Brussels, Chicago, Hong Kong, London, Los Angeles, New York, San Francisco, and Washington. For more information, visit www.steptoe.com.
